Accredited Investors Inc. Acquires 66 Shares of Becton, Dickinson and Company (NYSE:BDX)

Accredited Investors Inc. grew its holdings in Becton, Dickinson and Company (NYSE:BDX) by 7.3% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 967 shares of the medical instruments supplier’s stock after acquiring an additional 66 shares during the quarter. Accredited Investors Inc.’s holdings in Becton, Dickinson and Company were worth $226,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. MONECO Advisors LLC raised its stake in shares of Becton, Dickinson and Company by 19.1% in the 2nd quarter. MONECO Advisors LLC now owns 1,067 shares of the medical instruments supplier’s stock valued at $249,000 after buying an additional 171 shares in the last quarter. OFI Invest Asset Management lifted its position in shares of Becton, Dickinson and Company by 2.5% during the 2nd quarter. OFI Invest Asset Management now owns 4,153 shares of the medical instruments supplier’s stock worth $906,000 after buying an additional 101 shares during the period. Oakworth Capital Inc. raised its stake in Becton, Dickinson and Company by 20.8% during the second quarter. Oakworth Capital Inc. now owns 1,654 shares of the medical instruments supplier’s stock worth $387,000 after acquiring an additional 285 shares in the last quarter. Brookstone Capital Management boosted its stake in shares of Becton, Dickinson and Company by 12.4% in the 2nd quarter. Brookstone Capital Management now owns 13,179 shares of the medical instruments supplier’s stock valued at $3,085,000 after purchasing an additional 1,454 shares in the last quarter. Finally, Blue Trust Inc. lifted its holdings in Becton, Dickinson and Company by 180.2% during the 2nd quarter. Blue Trust Inc. now owns 2,382 shares of the medical instruments supplier’s stock valued at $589,000 after purchasing an additional 1,532 shares during the last quarter. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Up 0.0 %

Shares of NYSE BDX traded up $0.05 during midday trading on Tuesday, reaching $235.95. The company’s stock had a trading volume of 46,850 shares, compared to its average volume of 1,436,082. Becton, Dickinson and Company has a fifty-two week low of $218.75 and a fifty-two week high of $283.50. The stock has a 50 day simple moving average of $233.13 and a 200-day simple moving average of $236.14. The stock has a market capitalization of $68.19 billion, a price-to-earnings ratio of 51.96, a PEG ratio of 2.06 and a beta of 0.42. The company has a current ratio of 1.85, a quick ratio of 0.97 and a debt-to-equity ratio of 0.70.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, beating the consensus estimate of $3.31 by $0.19. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The company had revenue of $4.99 billion during the quarter, compared to analysts’ expectations of $5.08 billion. During the same quarter last year, the company earned $2.96 EPS. Becton, Dickinson and Company’s revenue for the quarter was up 2.3% compared to the same quarter last year. Equities research analysts predict that Becton, Dickinson and Company will post 13.06 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Stockholders of record on Monday, September 9th will be issued a $0.95 dividend. This represents a $3.80 annualized dividend and a dividend yield of 1.61%. The ex-dividend date of this dividend is Monday, September 9th. Becton, Dickinson and Company’s payout ratio is presently 83.70%.

Analysts Set New Price Targets

Several brokerages recently weighed in on BDX. Evercore ISI cut their price objective on shares of Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating on the stock in a report on Tuesday, July 2nd. StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Stifel Nicolaus upped their price target on Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Raymond James cut their price target on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research report on Friday, August 2nd. Finally, Barclays lifted their price target on shares of Becton, Dickinson and Company from $305.00 to $312.00 and gave the stock an “overweight” rating in a research report on Monday, May 6th. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $279.50.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 300 shares of the company’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $239.31, for a total value of $71,793.00. Following the sale, the senior vice president now owns 1,976 shares in the company, valued at $472,876.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.31% of the stock is owned by company insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.